PCSK9 Inhibitors Billing & Prior-Auth Playbook

What Is the PCSK9 Inhibitor Drug Class?

PCSK9 inhibitors are lipid-lowering agents that work by blocking proprotein convertase subtilisin/kexin type 9, an enzyme that degrades LDL receptors on hepatocytes. When PCSK9 is inhibited, more LDL receptors remain on the cell surface and clear more LDL-C from the bloodstream. The result is an LDL-C reduction of 50 to 60% beyond what maximally tolerated statin therapy alone achieves.

The class currently contains three FDA-approved agents in the United States: evolocumab (Repatha), alirocumab (Praluent), and inclisiran (Leqvio). Evolocumab and alirocumab are fully human monoclonal antibodies given by subcutaneous injection every two to four weeks. Inclisiran is a small interfering RNA (siRNA) that silences hepatic PCSK9 mRNA; it is dosed twice yearly after two initial loading injections, which changes the administrative model and billing pathway significantly.

Mechanism at the Molecular Level

The LDL receptor normally recycles to the hepatocyte surface after delivering LDL-C to the cell. PCSK9 binds the receptor in the endosome and diverts it to lysosomal degradation instead. Monoclonal antibody PCSK9 inhibitors bind circulating PCSK9 and prevent this interaction. Inclisiran acts upstream, reducing PCSK9 synthesis in the liver rather than neutralizing the secreted protein. Both approaches leave more functional LDL receptors available per hepatocyte cycle. 1

FDA-Approved Indications

Evolocumab carries FDA approval for: heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established cardiovascular disease in adults who need additional LDL-C lowering. 2 Alirocumab is approved for HeFH and ASCVD. 3 Inclisiran is approved for HeFH and ASCVD in adults on maximally tolerated statin therapy. 4 HoFH approval exists for evolocumab but not for inclisiran or alirocumab, a distinction payers check on every PA form.

Key Clinical Evidence Every Prescriber Must Know

Citing the correct trial data in your PA letter is the fastest way to convert a denial to an approval. Payer medical directors recognize the FOURIER and ODYSSEY OUTCOMES trials by name.

FOURIER Trial (Evolocumab)

The FOURIER trial enrolled 27,564 patients with established ASCVD who were already on optimized statin therapy. 5 At 48 weeks, evolocumab 140 mg every two weeks lowered LDL-C by 59% from a median baseline of 92 mg/dL. The primary composite endpoint (CV death, MI, stroke, unstable angina hospitalization, or coronary revascularization) fell by 15% relative risk reduction over 2.2 years (HR 0.85, 95% CI 0.79 to 0.92, P<0.001). The absolute risk reduction was 1.5 percentage points, yielding a number-needed-to-treat of 67 over 2.2 years.

ODYSSEY OUTCOMES Trial (Alirocumab)

ODYSSEY OUTCOMES followed 18,924 patients for a median of 2.8 years after acute coronary syndrome. 6 Alirocumab 75 to 150 mg every two weeks reduced MACE by 15% (HR 0.85, 95% CI 0.78 to 0.93, P<0.001) compared to placebo. In the prespecified subgroup with baseline LDL-C >100 mg/dL, the absolute risk reduction reached 3.4 percentage points. An all-cause mortality signal favored alirocumab (3.5% vs. 4.1%, P=0.026), though the trial was not powered solely for mortality.

ORION-10 and ORION-11 Trials (Inclisiran)

ORION-10 (N=1,561) and ORION-11 (N=1,617) showed inclisiran 284 mg twice yearly reduced LDL-C by approximately 52% from baseline at day 510 (P<0.001 for both trials). 7 Cardiovascular outcome data for inclisiran are anticipated from the ORION-4 trial (N=15,000, ongoing), which will influence future payer policies for this agent. 8

Statin Intolerance Data

The GAUSS-3 trial (N=511) specifically enrolled statin-intolerant patients and showed evolocumab 420 mg monthly lowered LDL-C by 52.8% more than ezetimibe (P<0.001) with significantly fewer muscle-related adverse events than atorvastatin rechallenge (0.7% vs. 32.5%, P<0.001). 9 Statin intolerance documentation in the PA chart should reference this trial or similar evidence rather than vague symptom lists.

Prescribing Criteria and Patient Selection

The 2022 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction specifies that PCSK9 inhibitors are indicated when LDL-C remains >70 mg/dL (1.8 mmol/L) in very-high-risk ASCVD or >100 mg/dL (2.6 mmol/L) in high-risk patients despite maximally tolerated statin plus ezetimibe. 10 The document states: "For patients with very high-risk ASCVD whose LDL-C remains >70 mg/dL on maximally tolerated statin and ezetimibe, a PCSK9 inhibitor is recommended (Class I, LOE A)."

Very-High-Risk ASCVD Definition

The ACC/AHA 2018 Cholesterol Guideline defines very-high-risk ASCVD as a history of multiple major ASCVD events or one major ASCVD event plus multiple high-risk conditions. 11 Major events include recent ACS (within 12 months), MI history, ischemic stroke history, or symptomatic peripheral artery disease. High-risk conditions include age >65, heterozygous FH, prior coronary revascularization not listed as a major event, diabetes, hypertension, CKD stage 3 to 4, current smoking, or persistently elevated LDL-C >100 mg/dL.

Documenting which specific criteria your patient meets, by name and code, is the single highest-yield action in the PA workflow. Payers with automated review systems match ICD-10 codes from the PA form against approved criteria lists.

Familial Hypercholesterolemia

FH diagnosis should be documented using the Simon Broome or Dutch Lipid Clinic Network (DLCN) criteria. 12 A DLCN score >8 points constitutes "definite FH." Genetic confirmation (LDLR, APOB, or PCSK9 pathogenic variant) strengthens the PA case considerably. HoFH patients often present with LDL-C >400 mg/dL and require evolocumab 420 mg monthly, with a separate FDA indication and a separate tier on most payer formularies. 13

Statin Intolerance Documentation

Payers define statin intolerance differently, but most commercial policies require a trial of at least two separate statins at any tolerated dose, one of which was rosuvastatin (a high-potency, low-myopathy statin). The chart should record: statin name, dose tried, duration, specific adverse effect (CK level if myopathy was the complaint, date of symptom onset, date of symptom resolution after discontinuation). Vague notes like "patient does not tolerate statins" generate automatic denials across nearly all payer platforms. 14

Dosing, Administration, and Monitoring

Dose and Schedule

Evolocumab is dosed 140 mg every two weeks or 420 mg monthly (SureClick autoinjector or Pushtronex monthly system). Alirocumab starts at 75 mg every two weeks; the dose may be titrated to 150 mg every two weeks if LDL-C reduction is insufficient at week 8. Inclisiran is 284 mg subcutaneously at day 1, day 90, then every six months thereafter.

The twice-yearly inclisiran schedule reduces the injection burden to two office visits per year. This matters for billing because inclisiran is typically administered in the physician office under a medical benefit (not pharmacy benefit) pathway, billed under CPT 96402 (chemotherapy administration, subcutaneous, per injection) or J3490/J3590 (unlisted drug codes) until a permanent J-code is assigned. 15

LDL-C Monitoring

Obtain a fasting lipid panel four to twelve weeks after initiating therapy to confirm response and to document the result for PA renewals. The ACC/AHA 2018 guideline recommends confirming LDL-C response at three months. 11 A measured LDL-C below goal on therapy is your best evidence for a renewal PA submission. Patients with HoFH who have very low baseline LDL-receptor activity may respond partially; monitor at four to eight weeks and adjust.

Safety Profile

The class is generally well tolerated. Injection site reactions occur in 2 to 5% of patients. Neurocognitive adverse events (confusion, memory impairment) were flagged in early postmarketing reports but the EBBINGHAUS substudy of FOURIER (N=1,204) found no significant difference between evolocumab and placebo on neurocognitive testing over 19 months. 16 Absolute LDL-C levels as low as 15 mg/dL were achieved in some FOURIER participants without safety signals over the study period.

Billing Pathways: Medical vs. Pharmacy Benefit

Commercial and Medicare Part D (Pharmacy Benefit)

Alirocumab and evolocumab are typically processed under the pharmacy benefit for self-administered injections at home. The patient or specialty pharmacy submits the claim using the National Drug Code (NDC). Specialty pharmacy networks handle most volume; your office initiates the PA and ships the prescription to a contracted specialty pharmacy. List AWP runs approximately $5,850, $6,500 per year; net price after manufacturer rebates and patient assistance programs varies widely by plan.

Inclisiran Under the Medical Benefit

Inclisiran is categorized as a physician-administered drug in many CMS and commercial frameworks. The office purchases or orders the drug, administers the injection during the visit, and bills under the medical benefit. Use ICD-10 diagnosis codes E78.00 (pure hypercholesterolemia, unspecified), E78.01 (familial hypercholesterolemia), or I25.10 (atherosclerotic heart disease, unspecified vessel) as primary codes. Pair with CPT 96402 for administration. A permanent J-code for inclisiran (J2861) became effective January 1, 2024, under the CMS 2024 OPPS final rule, simplifying billing considerably. 17

Buy-and-Bill vs. White Bagging

For inclisiran in office or hospital outpatient settings, confirm with each payer whether buy-and-bill or white bagging (specialty pharmacy ships drug to the office) is required. CMS Medicare Part B generally allows buy-and-bill for physician-administered drugs. Many commercial payers have shifted inclisiran to white bagging to capture rebates, which shifts inventory risk back to the specialty pharmacy.

Prior Authorization Step-by-Step Workflow

PA denial rates for PCSK9 inhibitors exceeded 50% at initial submission in a 2018 analysis published in JAMA Cardiology, but practices with structured PA workflows achieved approval rates above 80%. 18

Step 1: Gather Required Documentation Before Submission

Collect the following before opening the PA form: (1) Most recent fasting LDL-C with date (within 90 days preferred); (2) Current statin and dose, or documented reason for no statin; (3) Ezetimibe trial documentation (name, dose, duration, or contraindication); (4) ICD-10 codes for the primary indication; (5) ASCVD risk tier classification per ACC/AHA 2018; (6) For FH: DLCN score or genetic test result; (7) For statin intolerance: statin names tried, doses, adverse effects, and dates.

Step 2: Choose the Correct PA Form and Drug

Most payers maintain separate PA policies for each agent (evolocumab, alirocumab, inclisiran). Using the wrong form adds two to four business days. Confirm on the payer's formulary portal whether the preferred agent is evolocumab or alirocumab (some plans prefer one over the other based on rebate contracts). Inclisiran sits on a separate medical-benefit PA pathway from the pharmacy-benefit agents.

Step 3: Write a PA Letter That Mirrors Guideline Language

The PA letter should use the ACC/AHA guideline language verbatim. For example: "Per the 2022 ACC Expert Consensus Decision Pathway (Class I, LOE A), PCSK9 inhibitor therapy is indicated for this patient with very-high-risk ASCVD and LDL-C of [X] mg/dL on maximally tolerated rosuvastatin 40 mg plus ezetimibe 10 mg daily." Include the patient's specific LDL-C number, the specific statin dose, and the specific ACC/AHA risk tier. Generic letters produce generic denials.

Step 4: Submit and Track Turnaround

Commercial payer PA turnaround is typically 3 to 7 business days for non-urgent requests, 24 to 72 hours for urgent (expedited) requests. Medicare Advantage plans follow CMS Part D timelines: 72 hours urgent, 7 days standard. 19 Document the date of submission in the patient chart so you can track 30-day follow-up if no decision is received.

Step 5: Appeal Denied Authorizations

First-level appeals overturn approximately 30 to 40% of initial PA denials. The appeal letter should add: (1) A peer-reviewed citation for the specific indication (FOURIER for evolocumab, ODYSSEY OUTCOMES for alirocumab); (2) A statement of medical necessity signed by the prescribing physician; (3) A request for peer-to-peer review with the payer's medical director. Second-level appeals and external review are available under most state and federal law if the first appeal fails.

Formulary Positioning and Step Therapy

Most commercial plans require step therapy through high-intensity statins and ezetimibe before approving PCSK9 inhibitors. The standard step therapy sequence payers enforce is: (1) high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for a minimum of 90 days; (2) addition of ezetimibe 10 mg for a minimum of 90 days; (3) documented residual LDL-C above goal; (4) PCSK9 inhibitor initiation. 20

Some plans exempt patients from step therapy when the LDL-C is extremely elevated (>190 mg/dL at baseline, consistent with FH), when prior statin intolerance is fully documented, or when a recent ACS occurred within the past 90 days. Ask the plan's formulary team directly about these exemptions before submitting the PA; noting the exemption category on the form shortens processing time.

Formulary Tier and Cost-Sharing

PCSK9 inhibitors typically sit on specialty tier (tier 4 or tier 5) of commercial formularies, with cost-sharing of $100, $400 per month before manufacturer copay assistance applies. The Amgen Repatha patient assistance program covers patients with income below 600% of the federal poverty level at $0 copay. The Sanofi/Regeneron Praluent MyPraluent support program offers similar assistance. Connecting patients to these programs before the specialty pharmacy dispenses reduces abandonment rates dramatically.

Renewal PA Strategy

Most payers require PA renewal at 12 months. The renewal submission should include: (1) current LDL-C (ideally showing response to therapy, e.g., reduction of 40 to 60%); (2) any CV events that occurred during the treatment period; (3) re-affirmation of the original diagnosis code. A patient who achieved LDL-C <70 mg/dL on therapy will face fewer hurdles at renewal than a patient whose LDL-C remained above goal (though the latter may need dose adjustment rather than discontinuation).

Payers occasionally deny renewal when the LDL-C goal appears "achieved" and they believe the drug can be discontinued. The counter-argument is that goal attainment is evidence the drug is working and that discontinuation will return LDL-C to baseline, reinstating CV risk. Citing FOURIER's continuous benefit curve across achieved LDL-C levels supports this argument. 5

ICD-10 and NDC Quick Reference

Use precise ICD-10 codes on every PA form and claim. The most common PCSK9 inhibitor indications map as follows:

| Indication | ICD-10 Code | |---|---| | Familial hypercholesterolemia, heterozygous | E78.01 | | Familial hypercholesterolemia, homozygous | E78.02 | | Pure hypercholesterolemia, unspecified | E78.00 | | Atherosclerotic heart disease, unspecified | I25.10 | | Old MI | I25.2 | | Ischemic stroke sequelae | I69.30x | | Peripheral artery disease | I73.9 |

NDC codes for billing evolocumab (Repatha SureClick 140 mg/mL): 55513-0730-01. Alirocumab (Praluent 75 mg/mL): 0024-5917-01. Inclisiran (Leqvio 284 mg/1.5 mL): 0078-0865-61. Confirm current NDCs with the dispensing pharmacy; Amgen and Sanofi/Regeneron periodically add package configurations.

ACC/AHA Guideline Summary for Clinical Use

The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol places PCSK9 inhibitors at the top of the add-on therapy hierarchy for high- and very-high-risk patients. 11 The guideline states: "In patients with very high-risk ASCVD, if the LDL-C level remains >70 mg/dL (1.8 mmol/L) on maximally tolerated statin and ezetimibe therapy, it is reasonable to add a PCSK9 inhibitor (Class IIa, LOE A)." The 2022 ACC Expert Consensus upgraded this to Class I for the very-high-risk subgroup. 10

For patients with HeFH, a target LDL-C reduction of at least 50% is recommended by the European Atherosclerosis Society (EAS), and absolute LDL-C <70 mg/dL is the goal for those with concurrent ASCVD. 12